The United States Food and Drug Administration (FDA) published Thursday a list of pharmaceutical companies that include Basel-based Novartis and Roche, all of which are suspected of hindering the development of generic versions of their own medicines. Over 150 complaints were filed.
The FDA slammed the development of techniques designed to complicate or even prevent developers of generic drugs from accessing sufficient quantities of original preparations to be able to do comparative studies essential to any application for approval.
The authority said it has received more than 150 complaints over the alleged misuse of FDA programmes or agreements between pharmaceutical companies and distributors.
The FDA noted that it had not investigated these allegations.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
This content was published on
Each year, some half a million people die of malaria, many of them children. Switzerland is a world leader in research to combat the disease.
Swiss authorities allowed isopropanol exports to Syria
This content was published on
Switzerland authorised the export to Syria of the chemical isopropanol in 2014, which can be used to make sarin gas, RTS, reports.
Novartis and GSK CEOs set out diverging strategies
This content was published on
It is a tale of two newly minted chief executives, each looking to send a clear signal to investors about strategy and priorities.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.